A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging.

J Clin InvestJun 30, 2026 (epub)
Clinical ResearchOncology (Medical)Nuclear MedicineOpen access

Tingfei Gu, Zhao Chen, Bo Tang et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-arm phase I trial evaluated the safety and diagnostic performance of 68Ga-PFBC01 PET/CT in 50 patients with multiple myeloma. The study found that 68Ga-PFBC01 PET/CT had a sensitivity of 96.9% and specificity of 71.4%, outperforming 18F-FDG PET/CT. The tracer demonstrated potential for improving clinical decision-making.

Key findings

  • 68Ga-PFBC01 PET/CT showed a sensitivity of 96.9% compared to 84.6% for 18F-FDG PET/CT.
  • Specificity was 71.4% for 68Ga-PFBC01 versus 60.0% for 18F-FDG.
  • Imaging findings influenced clinical management in multiple cases, allowing therapy adjustments.
  • No serious adverse events were reported; only 4% experienced mild events.

Why it matters

The study highlights the potential of 68Ga-PFBC01 PET/CT as a more effective imaging tool for assessing multiple myeloma, which could lead to better-informed treatment decisions and improved patient outcomes.

Source

PubMed · PMID 42378054Free full text on PubMed Central

Published in J Clin Invest. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.